CHEOY (Cochlear) Beneish M-Score: -2.03 (As of Jun. 26, 2026)


CHEOY Cochlear Ltd CHEOY
62 GF Score
Price $41.68
GF Value $112.53
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear Beneish M-Score?

Cochlear CHEOY +3.12% 62 Beneish M-Score is -2.03 as of Jun. 26, 2026. GuruFocus rates CHEOY with a GF Score™ of 62/100 and a GF Value™ of $112.53 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Cochlear ranks worse than 80.55% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.03 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Cochlear's Beneish M-Score or its related term are showing as below:

CHEOY' s Beneish M-Score Range Over the Past 10 Years
Min: -2.65   Med: -2.4   Max: -2.02
Current: -2.03

During the past 13 years, the highest Beneish M-Score of Cochlear was -2.02. The lowest was -2.65. And the median was -2.40.


Cochlear Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Cochlear's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cochlear Beneish M-Score Chart

Cochlear Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.02 -2.65 -2.37 -2.40 -2.03

Cochlear Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -2.40 0.00 -2.03 0.00

CHEOY vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Cochlear's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cochlear Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cochlear's Beneish M-Score falls into.


CHEOY
62GF Score
Cochlear Ltd CHEOY
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cochlear Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cochlear for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1392+0.528 * 1.0151+0.404 * 1.0922+0.892 * 1.0276+0.115 * 0.9774
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9991+4.679 * 0.046017-0.327 * 0.9277
=-2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun25) TTM:Last Year (Jun24) TTM:
Total Receivables was $381 Mil.
Revenue was $1,525 Mil.
Gross Profit was $1,125 Mil.
Total Current Assets was $922 Mil.
Total Assets was $1,839 Mil.
Property, Plant and Equipment(Net PPE) was $349 Mil.
Depreciation, Depletion and Amortization(DDA) was $59 Mil.
Selling, General, & Admin. Expense(SGA) was $612 Mil.
Total Current Liabilities was $392 Mil.
Long-Term Debt & Capital Lease Obligation was $126 Mil.
Net Income was $253 Mil.
Gross Profit was $14 Mil.
Cash Flow from Operations was $155 Mil.
Total Receivables was $326 Mil.
Revenue was $1,484 Mil.
Gross Profit was $1,111 Mil.
Total Current Assets was $964 Mil.
Total Assets was $1,823 Mil.
Property, Plant and Equipment(Net PPE) was $343 Mil.
Depreciation, Depletion and Amortization(DDA) was $56 Mil.
Selling, General, & Admin. Expense(SGA) was $596 Mil.
Total Current Liabilities was $419 Mil.
Long-Term Debt & Capital Lease Obligation was $134 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(381.445 / 1525.456) / (325.83 / 1484.462)
=0.250053 / 0.219494
=1.1392

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1111.222 / 1484.462) / (1124.935 / 1525.456)
=0.748569 / 0.737442
=1.0151

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (922.396 + 349.089) / 1839.193) / (1 - (964.21 + 343.426) / 1822.776)
=0.308672 / 0.282613
=1.0922

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1525.456 / 1484.462
=1.0276

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(56.375 / (56.375 + 343.426)) / (58.854 / (58.854 + 349.089))
=0.141008 / 0.14427
=0.9774

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(611.914 / 1525.456) / (596.016 / 1484.462)
=0.401135 / 0.401503
=0.9991

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((125.977 + 392.122) / 1839.193) / ((134.197 + 419.323) / 1822.776)
=0.281699 / 0.303669
=0.9277

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(253.19 - 13.867 - 154.688) / 1839.193
=0.046017

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cochlear has a M-score of -2.05 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.03 mean?
Cochlear (CHEOY) has a Beneish M-Score of -2.03 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Cochlear and its competitors. According to the industry distribution chart, Cochlear ranks #617 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 80.5%.
Is Cochlear's Beneish M-Score too high?
Cochlear's current Beneish M-Score is -2.03. Based on the distribution chart, Cochlear ranks #617 out of 766 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cochlear has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #617 out of 766 companies for Beneish M-Score. This places Cochlear in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Cochlear and its competitors. Cochlear's current Beneish M-Score is -2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (CHEOY) is currently considered Significantly Undervalued. The stock's GF Value™ is $112.53, compared to a current price of $41.68 — trading 63% below its estimated fair value. The current Beneish M-Score is -2.03. Cochlear's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Cochlear (CHEOY), the current Beneish M-Score is -2.03 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cochlear (CHEOY) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of $41.68 is trading 63% below its estimated GF Value™ of $112.53. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for CHEOY:

  • Beneish M-Score: -2.03
  • GF Value™: $112.53 vs. price of $41.68 (63% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the CHEOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
62GF Score

Get the complete analysis for CHEOY

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.68
Price
$112.53
GF Value